DNMT1 Regulates IL-6- and TGF-β1-Induced Epithelial Mesenchymal Transition in Prostate Epithelial Cells

Multiple factors have been considered to play a role in the development of benign prostatic hyperplasia (BPH), including chronic inflammation, hormones, and epithelial-mesenchymal transition (EMT). Inflammation is regarded as one of the potential inducers of EMT. However, the mechanisms, modulating pro-inflammatory factors (IL-6 and TGF-β1) induce EMT features, have not yet been studied in BPH. In this study, we investigated whether DNA methyltransferases1 (DNMT1) could regulate IL-6 and TGF-β1 induce EMT. The expression of EMT features was analyzed in normal prostate epithelial cells (PrECs) and BPH1 cells. Real-time RT-PCR and western blotting were used to examine the expression of EMT features in IL-6- and TGF-β1-treated PrECs. Next, bisulfite sequencing PCR (BSP) methods were used to examine the DNA methylation level of the Cdh1 promoter region. The results showed that EMT features were increased in BPH1 cells, compared to PrECs. IL-6 and TGF-β1 treatment induced EMT features, including decreased E-cadherin expression. The results of BSP revealed significant DNA hypermethylation at the promoter region of Cdh1 after IL-6 and TGF-β1 exposure, which was rescued when pretreated with 5-Aza or TGF-β1 antibody. Moreover, the protein expression and methyltransferase activity of DNMT1 were also increased after IL-6 and TGF-β1 induction. Collectively, our study showed that IL-6 and TGF-β1 could activate DNMT1 and directly regulate the expression of E-cadherin in PrECs, providing a potential therapeutic candidate for BPH.

[1]  X. Zu,et al.  LPS/TLR4 Signaling Enhances TGF-β Response Through Downregulating BAMBI During Prostatic Hyperplasia , 2016, Scientific Reports.

[2]  D. Choubey,et al.  Hypoxia primes human normal prostate epithelial cells and cancer cell lines for the NLRP3 and AIM2 inflammasome activation , 2016, Oncotarget.

[3]  Melissa M. Norström,et al.  Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes , 2016, Oncotarget.

[4]  Kimberly P Keil,et al.  DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate. , 2015, Epigenomics.

[5]  Chin-Lee Wu,et al.  DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. , 2015, The American journal of pathology.

[6]  A. Olumi,et al.  Personalized medicine for the management of benign prostatic hyperplasia. , 2014, The Journal of urology.

[7]  Kimberly P Keil,et al.  DNA methylation of E-cadherin is a priming mechanism for prostate development. , 2014, Developmental biology.

[8]  N. Kyprianou,et al.  Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression , 2013, Translational andrology and urology.

[9]  B. Djavan,et al.  Correlation between benign prostatic hyperplasia and inflammation , 2013, Current opinion in urology.

[10]  Chawnshang Chang,et al.  Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. , 2012, Molecular endocrinology.

[11]  T. Jenuwein,et al.  In Vivo Control of CpG and Non-CpG DNA Methylation by DNA Methyltransferases , 2012, PLoS genetics.

[12]  Ximing J. Yang,et al.  TGF-β Regulates DNA Methyltransferase Expression in Prostate Cancer, Correlates with Aggressive Capabilities, and Predicts Disease Recurrence , 2011, PloS one.

[13]  A. Kozubík,et al.  TGF‐β1‐induced EMT of non‐transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug , 2011, The Prostate.

[14]  Chin-Lee Wu,et al.  Reduced levels of 5‐α reductase 2 in adult prostate tissue and implications for BPH therapy , 2011, The Prostate.

[15]  A. Kozubík,et al.  TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. , 2010, Cellular signalling.

[16]  I. Thompson,et al.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2010, American journal of epidemiology.

[17]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[18]  A. Kozubík,et al.  Dynamic Monitoring of Cellular Remodeling Induced by the Transforming Growth Factor-β1 , 2009, Biological Procedures Online.

[19]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[20]  Mario Maggi,et al.  Human Benign Prostatic Hyperplasia Stromal Cells As Inducers and Targets of Chronic Immuno-Mediated Inflammation1 , 2009, The Journal of Immunology.

[21]  J. Gustafsson,et al.  A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia , 2009, Proceedings of the National Academy of Sciences.

[22]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[23]  C. Roehrborn,et al.  Pathology of benign prostatic hyperplasia , 2008, International Journal of Impotence Research.

[24]  K. Helin,et al.  Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor , 2008, Molecular and Cellular Biology.

[25]  C. Allis,et al.  DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA , 2007, Nature.

[26]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[27]  Hye-Jin Kim,et al.  Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation. , 2013, Biochimica et biophysica acta.

[28]  A. Carvalho,et al.  Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. , 2005, DNA and cell biology.

[29]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.